Lantheus (NASDAQ:LNTH) Updates FY24 Earnings Guidance

Lantheus (NASDAQ:LNTH) issued an update on its FY24 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $6.65-6.70 for the period, compared to the consensus earnings per share estimate of $6.66. The company issued revenue guidance of $1.51-1.52 billion, compared to the consensus revenue estimate of $1.52 billion. Lantheus also updated its FY 2024 guidance to 6.650-6.700 EPS.

Lantheus Price Performance

NASDAQ LNTH opened at $114.96 on Wednesday. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.68 and a quick ratio of 4.41. The stock’s fifty day moving average price is $108.41 and its 200 day moving average price is $95.60. Lantheus has a 1 year low of $50.20 and a 1 year high of $126.89. The company has a market cap of $7.98 billion, a price-to-earnings ratio of 18.85 and a beta of 0.51.

Wall Street Analyst Weigh In

LNTH has been the topic of several research reports. Redburn Atlantic initiated coverage on Lantheus in a research report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 target price on the stock. B. Riley upped their target price on Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Leerink Partners increased their price target on Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, July 11th. JMP Securities cut their price target on Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 1st. Finally, Truist Financial cut their price target on Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a research report on Thursday, August 1st. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $126.00.

Insider Transactions at Lantheus

In other news, Director Gerard Ber sold 15,500 shares of the stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the sale, the director now directly owns 21,221 shares of the company’s stock, valued at $2,047,402.08. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other news, President Paul Blanchfield sold 2,000 shares of the stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $96.39, for a total transaction of $192,780.00. Following the sale, the president now directly owns 98,980 shares of the company’s stock, valued at $9,540,682.20. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Gerard Ber sold 15,500 shares of the firm’s stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the completion of the transaction, the director now directly owns 21,221 shares in the company, valued at $2,047,402.08. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.50% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.